thebench.bio #1 Ecosystem for the Bio-Tech Industry
All Regulatory Affairs questions

Question 18 of 20 Advanced Scenario

How would you plan an agency interaction when the pivotal evidence has a major uncertainty?

Short answer

Name the uncertainty plainly, quantify it, and come with a proposed way to resolve or manage it, such as a sensitivity analysis, an additional study or a post-approval commitment. Ask early, in a formal meeting with specific questions, rather than hoping reviewers miss it.

Why

Regulators find major uncertainties anyway, and finding them first in a review damages trust. Examples include a primary endpoint result that depends on how missing data are handled, a single pivotal trial with a borderline p value, or a key site with inspection findings. In the US, a pre-NDA or pre-BLA meeting, a Type B meeting under PDUFA VII, is the natural place.

In the EU, scientific advice or a pre-submission meeting serves the same purpose. The briefing package should state the issue, show its size through sensitivity analyses under different assumptions, and explain why the conclusion holds or what would change it. Then propose a path: additional analyses, a supportive dataset, a confirmatory study, or, where justified, an expedited route such as accelerated approval or conditional marketing authorisation with clear post-approval obligations.

Ask specific questions: 'Does the agency agree these tipping point analyses address the missing data concern?' The answer shapes whether to file now, file with commitments, or run another study.

A strong answer covers

  • Disclose the uncertainty proactively
  • Quantify with sensitivity analyses
  • Propose a resolution or management path
  • Choose the right forum in US and EU
  • Specific questions that lead to a filing decision

Common mistakes

  • Hiding the weakness and hoping reviewers miss it.
  • Bringing the problem without any proposed solution.
  • Asking open questions that produce vague advice.